risk of semaglutide VA Clinicians Should Counsel Initiators About a 2-Fold Greater Vision Loss From 'Eye Stroke' Semaglutide: Shedding pounds, weighing risks

What Should Patients Ask Before Considering a Compounded Peptide

For decades, metformin has been the backbone of type 2 diabetes therapy

The drug repositioning activity is based on in vivo and in vitro tests

Starting at $175/month Targets GLP-1 receptors only Average 1517% body weight loss (STEP trial data) Once-weekly subcutaneous injection Strong evidence for cardiovascular benefit Often the right starting medication Compounded by licensed 503A pharmacy Patients new to GLP-1 therapy, those with cardiovascular risk factors, or anyone seeking a well-studied first-line option with proven, sustainable results

The only question is whether it's right for you